risks of glp-1 drugs Part 2 a 3-Part Series; Medications for Weight Loss Glucagon-like Receptor-1 agonists for obesity:
Description
This is a crucial finding, as Metabolic Dysfunction-Associated Steatohepatitis (MASH) is a major driver of chronic disease and shortened healthspan
That study enrolled 3,417 adults with obesity or overweight and without type 2 diabetes, and showed a mean weight loss of 22.7% at 68 weeks in patients who remained on treatment
Suicidal ideation is associated with the use of various weight reduction drugs [67,68]
GLP1 RA therapy may be continued preoperatively in patients without an elevated risk of delayed gastric emptying and aspiration
Many older adults with dementia have mixed brain pathology
